Tivicay approved in Europe in new dispersible tablet for children with HIVViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living Share XTivicay approved in Europe in new dispersible tablet for children with HIVhttps://pharmaphorum.com/news/tivicay-approved-in-europe-in-new-dispersible-tablet-for-children-with-hiv/
Shionogi and Tetra expand partnership ahead of Alzheimer’s trial readoutShionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a Share XShionogi and Tetra expand partnership ahead of Alzheimer’s trial readouthttps://pharmaphorum.com/news/shionogi-and-tetra-expand-partnership-ahead-of-alzheimers-trial-readout/
Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
UK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMCShionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available Share XUK’s NHS to fund Shionogi’s Mulpleo after backing from NICE and SMChttps://pharmaphorum.com/news/uks-nhs-to-fund-shionogis-mulpleo-after-backing-from-nice-and-smc/
Roche’s Tamiflu successor on target in phase 3 trialA trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, Share XRoche’s Tamiflu successor on target in phase 3 trialhttps://pharmaphorum.com/news/roches-tamiflu-successor-on-target-in-phase-3-trial/
ViiV’s Dovato HIV pill approved in EUViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over Share XViiV’s Dovato HIV pill approved in EUhttps://pharmaphorum.com/news/viivs-dovato-hiv-pill-approved-in-eu/
Sandoz to commercialise opioid induced constipation tablet in EUAs it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi Share XSandoz to commercialise opioid induced constipation tablet in EUhttps://pharmaphorum.com/news/sandoz-to-commercialise-opioid-induced-constipation-tablet-in-eu/
Shionogi’s Mulpleta gets FDA green light for patients with liver diseaseThe US drug regulator has approved Mulpleta (lusutrombopag) as a treatment for thrombocytopenia in certain patients with chronic Share XShionogi’s Mulpleta gets FDA green light for patients with liver diseasehttps://pharmaphorum.com/news/shionogis-mulpleta-gets-fda-green-light-for-patients-with-liver-disease/
